These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 35091441)

  • 1. Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer.
    Blum JL; Laird AD; Litton JK; Rugo HS; Ettl J; Hurvitz SA; Martin M; Roché HH; Lee KH; Goodwin A; Chen Y; Lanzalone S; Chelliserry J; Czibere A; Hopkins JF; Albacker LA; Mina LA
    Clin Cancer Res; 2022 Apr; 28(7):1383-1390. PubMed ID: 35091441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Loss of Heterozygosity of
    Mizrahi AG; Hamad H; Gugenheim A; Nisman B; Kuznetz A; David IB; Gelfend Y; Cohen S; Zick A; Sheva K; Nechushtan H; Peretz T; Meirovitz A
    Anticancer Res; 2022 Nov; 42(11):5257-5263. PubMed ID: 36288893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer.
    Cruz C; Castroviejo-Bermejo M; Gutiérrez-Enríquez S; Llop-Guevara A; Ibrahim YH; Gris-Oliver A; Bonache S; Morancho B; Bruna A; Rueda OM; Lai Z; Polanska UM; Jones GN; Kristel P; de Bustos L; Guzman M; Rodríguez O; Grueso J; Montalban G; Caratú G; Mancuso F; Fasani R; Jiménez J; Howat WJ; Dougherty B; Vivancos A; Nuciforo P; Serres-Créixams X; Rubio IT; Oaknin A; Cadogan E; Barrett JC; Caldas C; Baselga J; Saura C; Cortés J; Arribas J; Jonkers J; Díez O; O'Connor MJ; Balmaña J; Serra V
    Ann Oncol; 2018 May; 29(5):1203-1210. PubMed ID: 29635390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness of talazoparib for patients with germline BRCA1/2 mutated HER2-negative advanced breast cancer in China and the US.
    Pan J; Ren N; Ren L; Yang Y; Xu Q
    Sci Rep; 2024 Jun; 14(1):13935. PubMed ID: 38886516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial.
    Litton JK; Hurvitz SA; Mina LA; Rugo HS; Lee KH; Gonçalves A; Diab S; Woodward N; Goodwin A; Yerushalmi R; Roché H; Im YH; Eiermann W; Quek RGW; Usari T; Lanzalone S; Czibere A; Blum JL; Martin M; Ettl J
    Ann Oncol; 2020 Nov; 31(11):1526-1535. PubMed ID: 32828825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resurrection of PARP Inhibitors in Breast Cancer.
    Lyons TG; Robson ME
    J Natl Compr Canc Netw; 2018 Sep; 16(9):1150-1156. PubMed ID: 30181424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Update on PARP Inhibitors in Breast Cancer.
    Zimmer AS; Gillard M; Lipkowitz S; Lee JM
    Curr Treat Options Oncol; 2018 Apr; 19(5):21. PubMed ID: 29644491
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Effective Epigenetic-PARP Inhibitor Combination Therapy for Breast and Ovarian Cancers Independent of BRCA Mutations.
    Pulliam N; Fang F; Ozes AR; Tang J; Adewuyi A; Keer H; Lyons J; Baylin SB; Matei D; Nakshatri H; Rassool FV; Miller KD; Nephew KP
    Clin Cancer Res; 2018 Jul; 24(13):3163-3175. PubMed ID: 29615458
    [No Abstract]   [Full Text] [Related]  

  • 9. Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial.
    Hurvitz SA; Gonçalves A; Rugo HS; Lee KH; Fehrenbacher L; Mina LA; Diab S; Blum JL; Chakrabarti J; Elmeliegy M; DeAnnuntis L; Gauthier E; Czibere A; Tudor IC; Quek RGW; Litton JK; Ettl J
    Oncologist; 2020 Mar; 25(3):e439-e450. PubMed ID: 32162822
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Talazoparib Versus Chemotherapy in Patients with HER2-negative Advanced Breast Cancer and a Germline BRCA1/2 Mutation Enrolled in Asian Countries: Exploratory Subgroup Analysis of the Phase III EMBRACA Trial.
    Lee KH; Sohn J; Goodwin A; Usari T; Lanzalone S; Im SA; Kim SB
    Cancer Res Treat; 2021 Oct; 53(4):1084-1095. PubMed ID: 33781053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Development of the PARP inhibitor talazoparib for the treatment of advanced
    Hobbs EA; Litton JK; Yap TA
    Expert Opin Pharmacother; 2021 Oct; 22(14):1825-1837. PubMed ID: 34309473
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Talazoparib to treat BRCA-positive breast cancer.
    Guney Eskiler G
    Drugs Today (Barc); 2019 Jul; 55(7):459-467. PubMed ID: 31347614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BRCA1/2 testing: therapeutic implications for breast cancer management.
    Tung NM; Garber JE
    Br J Cancer; 2018 Jul; 119(2):141-152. PubMed ID: 29867226
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of talazoparib monotherapy in patients with wild-type BRCA1 and BRCA2 with a mutation in other homologous recombination genes.
    Gruber JJ; Afghahi A; Timms K; DeWees A; Gross W; Aushev VN; Wu HT; Balcioglu M; Sethi H; Scott D; Foran J; McMillan A; Ford JM; Telli ML
    Nat Cancer; 2022 Oct; 3(10):1181-1191. PubMed ID: 36253484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neoadjuvant Talazoparib for Patients With Operable Breast Cancer With a Germline
    Litton JK; Scoggins ME; Hess KR; Adrada BE; Murthy RK; Damodaran S; DeSnyder SM; Brewster AM; Barcenas CH; Valero V; Whitman GJ; Schwartz-Gomez J; Mittendorf EA; Thompson AM; Helgason T; Ibrahim N; Piwnica-Worms H; Moulder SL; Arun BK
    J Clin Oncol; 2020 Feb; 38(5):388-394. PubMed ID: 31461380
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Homologous Recombination Defects and Mutations in DNA Damage Response (DDR) Genes Besides
    Voutsadakis IA; Stravodimou A
    Anticancer Res; 2023 Mar; 43(3):967-981. PubMed ID: 36854505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase II Study of Talazoparib after Platinum or Cytotoxic Nonplatinum Regimens in Patients with Advanced Breast Cancer and Germline
    Turner NC; Telli ML; Rugo HS; Mailliez A; Ettl J; Grischke EM; Mina LA; Balmaña J; Fasching PA; Hurvitz SA; Wardley AM; Chappey C; Hannah AL; Robson ME;
    Clin Cancer Res; 2019 May; 25(9):2717-2724. PubMed ID: 30563931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes.
    Walsh EM; Mangini N; Fetting J; Armstrong D; Chan IS; Connolly RM; Fiallos K; Lehman J; Nunes R; Petry D; Reynolds J; Shah M; Smith KL; Visvanathan K; Lauring J; Park BH; Stearns V; Wolff AC
    Clin Breast Cancer; 2022 Jun; 22(4):319-325. PubMed ID: 35074264
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib.
    McCann KE
    Future Oncol; 2019 May; 15(15):1707-1715. PubMed ID: 30912451
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative efficacy, safety, and acceptability of single-agent poly (ADP-ribose) polymerase (PARP) inhibitors in
    Wang J; Zhang Y; Yuan L; Ren L; Zhang Y; Qi X
    Aging (Albany NY); 2020 Nov; 13(1):450-459. PubMed ID: 33257598
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.